SBI-1301

N/A

Report date: 2024/03/28 18:09:14

Base Information

Drug NameSBI-1301
Drug Alias NameSBI-1301
ClassificationSmall molecules > Synthetic peptide > Peptide drug conjugate (PDC)
Mechanisms of ActionTransient receptor potential cation channel subfamily V member 6 modulators
TargetsTransient receptor potential cation channel subfamily V member 6
Therapy Area/IndicationsSolid tumoursProstatic NeoplasmsOvarian Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesSoricimed Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesSoricimed Biopharma Inc
Active IndicationsSolid tumoursProstatic NeoplasmsOvarian Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A